[Ru(pipe)(dppb)(bipy)]PF₆: A novel ruthenium complex that effectively inhibits ERK activation and cyclin D1...

Area of Science:

• Oncology
• Medicinal Chemistry
• Biochemistry

Background:

• Lung cancer is the most common cancer globally, with low survival rates in Brazil.
• There is a need for novel chemotherapeutic agents beyond platinum-based drugs.
• Ruthenium compounds show promise as less toxic, more selective anticancer agents.

Purpose of the Study:

• To evaluate the antitumor potential of a novel ruthenium(II) complex, [Ru(pipe)(dppb)(bipy)]PF6 (PIPE).
• To assess PIPE's effects on non-small cell lung cancer (A549) cell line viability, proliferation, cell cycle, and apoptosis.

Main Methods:

• Treatment of A549 lung cancer cells with varying concentrations of PIPE.
• Cell viability and proliferation assays.
• Cell cycle analysis using flow cytometry.
• Western blot analysis for cyclin D1 and ERK phosphorylation.
• Apoptosis induction assessment via intrinsic pathway markers.

Main Results:

• PIPE significantly reduced A549 cell viability and proliferation.
• A concentration of 9μM PIPE induced G0/G1 cell cycle arrest, decreasing S-phase cells.
• PIPE reduced cyclin D1 expression and ERK phosphorylation, indicating antiproliferative effects.
• A concentration of 18μM PIPE induced apoptosis through the intrinsic pathway.

Conclusions:

• The ruthenium(II) complex PIPE demonstrates significant antitumor potential against non-small cell lung cancer.
• PIPE exhibits antiproliferative and cytotoxic effects by modulating cell cycle progression and inducing apoptosis.
• PIPE is a promising candidate for further investigation in preclinical in vivo models for lung cancer treatment.